Literature DB >> 10644911

Pleural mesothelioma and membranous nephropathy.

K Galesic1, B Bozic, R Heinzl, M Scukanec-Spoljar, V Bozikov.   

Abstract

Underlying malignancy has been thought to be responsible for 5-10% of the cases of membranous nephropathy in adults, with the risk being highest in patients over the age of 60 years. Solid tumors such as carcinomas of lung or colon, are most often involved. It is presumed that tumor antigens are deposited in the glomeruli; this is followed by antibody deposition and complement activation, leading to epithelial cell and basement membrane injury and proteinuria due to the associated increase in glomerular permeability. We describe a patient with a resistant nephrotic syndrome and massive proteinuria due to membranous nephropathy associated with pleural mesothelioma. Copyright 1999 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644911     DOI: 10.1159/000045541

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  5 in total

Review 1.  Minimal change disease associated with malignant pleural mesothelioma: case report and review of the literature.

Authors:  Halil Yildiz; Stoian Ioana Andreea; Delphine Hoton; Jean Cyr Yombi
Journal:  BMJ Case Rep       Date:  2016-12-19

2.  Membranous nephropathy associated with malignant pleural mesothelioma in an adult patient: A case report.

Authors:  Xinyu Pu; Yanna Dou; Dong Liu; Shan Lu; Songxia Quan; Xiaoxue Zhang; Shuang Ma; Zhanzheng Zhao
Journal:  Mol Clin Oncol       Date:  2016-08-04

3.  Mesothelioma of the testis and nephrotic syndrome: a case report.

Authors:  Justine Bacchetta; Dominique Ranchère; Frédérique Dijoud; Jean-Pierre Droz
Journal:  J Med Case Rep       Date:  2009-06-05

4.  Concomitant Nephrotic Syndrome and Cryoglobulinemia in a Case of Malignant Mesothelioma.

Authors:  Kei Nagai; Hiroaki Tachi; Kohei Inoue; Atsushi Ueda
Journal:  Case Rep Nephrol       Date:  2022-09-28

5.  Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab.

Authors:  Jamie S Lin; Daniel Y Wang; Omar Mamlouk; William F Glass; Maen Abdelrahim; Cassian Yee; Ala Abudayyeh
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.